Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 4, 2013, Pages 246-251

  Freedman, D Michal ^a   Kuncl, Ralph W ^b   Weinstein, Stephanie J ^a   Malila, Nea ^c,d   Virtamo, Jarmo ^e   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF REDLANDS   (United States)

^c FINNISH CANCER REGISTRY   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Amyotrophic lateral sclerosis; Cohort studies; Risk factors in epidemiology; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; PLACEBO;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD SAMPLING; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; COHORT STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; VITAMIN E;

EID: 84877871089     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2012.745570     Document Type: Article

References (33)

1. Rowland LP, S hneider NA. A myotrophic lateral sclerosis. N Engl J Med. 2001; 344 : 1688-700 (Pubitemid 32479968)
2. Andersen PM, A l-Chalabi A. C linical genetics of amyotrophic lateral sclerosis:What do we really know? Nat Rev Neurol. 2011; 7 : 603-15
3. Simpson EP, Y en A A, A ppel SH. O xidative stress: A common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol. 2003; 15 : 730-6 (Pubitemid 38156299)
4. Barber SC, S haw PJ. O xidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010; 48 : 629-41
5. Gurney ME, C utting FB, Z hai P, D oble A, T aylor CP, A ndrus P.K.et al. Benefi t of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996; 39 : 147-57 (Pubitemid 26071564)
6. Desnuelle C, D ib M, G arrel C, F avier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2 : 9-18 (Pubitemid 32472143)
7. Graf M, E cker D, H orowski R, K ramer B, R iederer P, G erlach M.et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole:Results of a placebocontrolled double-blind study. J Neural Transm. 2005; 112 : 649-60 (Pubitemid 40591197)
8. Orrell RW, L ane JM, R oss MA. A ntioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004 : CD002829
9. Wang H, O 'Reilly E J, W eisskopf M G, L ogroscino G, McCullough ML, Schatzkin A.et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: A pooled analysis of data from fi ve prospective cohort studies. Am J Epidemiol. 2011; 173 : 595-602
10. Ascherio A, W eisskopf M G, O 'Reilly E J, J acobs E J, McCullough ML, Calle E.E.et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol. 2005; 57 : 104-10 (Pubitemid 40053321)
11. The alpha-tocopherol, beta-carotene lung cancer prevention study: Design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol. 1994; 4 : 1-10
12. The effect of vitamin E and beta-carotene on the incidence of lung cancer. and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994; 330 : 1029-35
13. Pietinen P, H artman AM, H aapa E, R asanen L, H aapakoski J, Palmgren J.et al. Reproducibility and validity of dietary assessment instruments. II. A qualitative food frequency questionnaire. Am J Epidemiol. 1988; 128 : 667-76
14. Milne D B, B otnen J. R etinol, alpha-tocopherol, lycopene, and alpha- and beta-carotene simultaneously determined in plasma by isocratic liquid chromatography. Clin Chem. 1986; 32 : 874-6 (Pubitemid 17036507)
15. Brooks BR, M iller RG, S wash M, M unsat T L. E l Escorial revisited:Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1 : 293-9
16. Wang H, O 'Reilly EJ, W eisskopf MG, L ogroscino G, McCullough ML, Thun M.J.et al. Smoking and risk of amyotrophic lateral sclerosis: A pooled analysis of fi ve prospective cohorts. Arch Neurol. 2011; 68 : 207-13
17. Alonso A, L ogroscino G, H ernan MA. S moking and the risk of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010; 81 : 1249-52
18. Gallo V, B ueno-De-Mesquita H B, V ermeulen R, A ndersen P M, Kyrozis A, Linseisen J.et al. Smoking and risk for amyotrophic lateral sclerosis: Analysis of the EPIC cohort. Ann Neurol. 2009; 65 : 378-85
19. Willett W, S tampfer MJ. T otal energy intake: Implications for epidemiologic analyses. Am J Epidemiol. 1986; 124 : 17-27 (Pubitemid 16095831)
20. Rao A V, B alachandran B. R ole of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci. 2002; 5 : 291-309 (Pubitemid 35174629)
21. Bonnefont-Rousselot D, L acomblez L, J audon M, L epage S, Salachas F, Bensimon G.et al. Blood oxidative stress in amyotrophic lateral sclerosis. J Neurol Sci. 2000; 178 : 57-62
22. Bogdanov M, B rown R H, M atson W, S mart R, H ayden D, O'Donnell H et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 2000; 29 : 652-8
23. Ferrante RJ, B rowne SE, S hinobu LA, B owling A C, B aik MJ, MacGarvey U.et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997; 69 : 2064-74 (Pubitemid 27452754)
24. Troy CM, S helanski ML. D own-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci U S A. 1994; 91 : 6384-7 (Pubitemid 24200665)
25. Liu R, L i B, F lanagan SW, O berley LW, G ozal D, Q iu M. Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1- mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. J Neurochem. 2002; 80 : 488-500 (Pubitemid 36383032)
26. Ricciarelli R, Z ingg JM, A zzi A. V itamin E: Protective role of a Janus molecule. FASEB J. 2001; 15 : 2314-25 (Pubitemid 33063160)
27. Zingg JM, A zzi A. N on-antioxidant activities of vitamin E. Curr Med Chem. 2004; 11 : 1113-33 (Pubitemid 38585057)
28. Berman K, B rodaty H. T ocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs. 2004; 18 : 807-25 (Pubitemid 39410103)
29. Halliwell B. R ole of free radicals in the neurodegenerative diseases:Therapeutic implications for antioxidant treatment. Drugs Aging. 2001; 18 : 685-716 (Pubitemid 32948277)
30. Traber MG, S tevens JF. V itamins C and E: Benefi cial effects from a mechanistic perspective. Free Radic Biol Med. 2011; 51 : 1000-13
31. Ouahchi K, A rita M, K ayden H, H entati F, B en Hamida M, Sokol R.et al. Ataxia with isolated vitamin E defi ciency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet. 1995; 9 : 141-5
32. Muller DP, L loyd JK, W olff OH. V itamin E and neurological function. Lancet. 1983; 1 : 225-8
33. Wright M E, L awson K A, W einstein S J, P ietinen P, T aylor P R, Virtamo J.et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specifi c mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 2006; 84 : 1200-7 (Pubitemid 44730393)